This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Nalidixic acid

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Administration is oral.

Indications:

  • urinary tract infections

Cautions include:

  • renal impairment
  • pregnancy and breast feeding
  • G6PD deficiency
  • patients with AIDS - anaphylaxis has been reported
  • alkalinity of urine
  • inadequate fluid intake
  • avoid strong sunlight
  • false positive urinary glucose is tested for reducing substances

Contra-indications include:

  • history of convulsive disorders
  • porphyria

Side-effects include:

  • nausea and vomiting
  • dizziness, headache and fatigue
  • confusion
  • convulsions
  • rash and pruritus
  • joint pain
  • photosensitivity
  • diarrhoea
  • dyspepsia
  • abdominal pain
  • disturbances in liver enzymes and in serum bilirubin, urea or creatinine
  • eosinophilia
  • myalgia and muscle weakness
  • jaundice, visual disturbances

Note that with systemic and inhaled fluoroquinolones there is small increased risk of aortic aneurysm and dissection; advice for prescribing in high-risk patients (1)

Reference:

  • MHRA - Drug Safety Update November 2018

The summary of product characteristics must be consulted before prescribing this drug.

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.